Sumiko Okubo

403 total citations
25 papers, 296 citations indexed

About

Sumiko Okubo is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sumiko Okubo has authored 25 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sumiko Okubo's work include Lung Cancer Research Studies (4 papers), Peptidase Inhibition and Analysis (4 papers) and HER2/EGFR in Cancer Research (4 papers). Sumiko Okubo is often cited by papers focused on Lung Cancer Research Studies (4 papers), Peptidase Inhibition and Analysis (4 papers) and HER2/EGFR in Cancer Research (4 papers). Sumiko Okubo collaborates with scholars based in Japan, United States and Switzerland. Sumiko Okubo's co-authors include Hiroshi Sonoo, Junichi Kurebayashi, Yutaka Yamamoto, Katsuhiro Tanaka, Takemi Otsuki, Masahiko Ikeda, Tsunehisa Nomura, Kiyoshi Udagawa, Masafumi Kurosumi and Yutaka Fujiwara and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Sumiko Okubo

24 papers receiving 289 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sumiko Okubo Japan	10	165	116	68	67	40	25	296
Albaha Barqawi United States	5	167 1.0×	107 0.9×	187 2.8×	36 0.5×	70 1.8×	10	351
Mihály Bak Hungary	12	119 0.7×	152 1.3×	56 0.8×	42 0.6×	32 0.8×	23	335
L. Hart United States	11	254 1.5×	220 1.9×	183 2.7×	24 0.4×	66 1.6×	25	518
Bastianina Canu Italy	10	197 1.2×	136 1.2×	103 1.5×	22 0.3×	84 2.1×	15	346
Kati Servan Germany	6	119 0.7×	224 1.9×	24 0.4×	46 0.7×	105 2.6×	6	389
Andy Protter United States	5	158 1.0×	150 1.3×	60 0.9×	20 0.3×	38 0.9×	7	261
Marianna Sirico Italy	12	199 1.2×	172 1.5×	125 1.8×	36 0.5×	129 3.2×	34	406
S. Muthuramalingam United Kingdom	6	190 1.2×	85 0.7×	44 0.6×	16 0.2×	59 1.5×	10	346
Ben Staal United States	9	140 0.8×	219 1.9×	62 0.9×	27 0.4×	61 1.5×	14	365
Matteo Capaia Italy	12	114 0.7×	112 1.0×	77 1.1×	13 0.2×	60 1.5×	14	384

Countries citing papers authored by Sumiko Okubo

Since Specialization

Citations

This map shows the geographic impact of Sumiko Okubo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sumiko Okubo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sumiko Okubo more than expected).

Fields of papers citing papers by Sumiko Okubo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sumiko Okubo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sumiko Okubo. The network helps show where Sumiko Okubo may publish in the future.

Co-authorship network of co-authors of Sumiko Okubo

This figure shows the co-authorship network connecting the top 25 collaborators of Sumiko Okubo. A scholar is included among the top collaborators of Sumiko Okubo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sumiko Okubo. Sumiko Okubo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tolcher, Anthony W., Tanya B. Dorff, Sumiko Okubo, et al.. (2025). Phase 1, open-label, first-in-human study of ABBV-969, a dual variable antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology. 43(16_suppl).

Asada, Noboru, Satoru Takada, Chikashi Yoshida, et al.. (2023). Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan. Japanese Journal of Clinical Oncology. 53(7). 595–603. 3 indexed citations

Goto, Hideki, Satoshi Ito, Masahiro Kizaki, et al.. (2023). Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma. International Journal of Clinical Oncology. 29(2). 232–240. 3 indexed citations

Fujiwara, Yutaka, Hirotsugu Kenmotsu, Noboru Yamamoto, et al.. (2021). Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Cancer Medicine. 10(7). 2350–2358. 10 indexed citations

Yamauchi, Takahiro, Chikashi Yoshida, Kensuke Usuki, et al.. (2021). Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy. Japanese Journal of Clinical Oncology. 51(9). 1372–1382. 5 indexed citations

Izutsu, Koji, Kazuhito Yamamoto, Koji Kato, et al.. (2020). Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. International Journal of Hematology. 113(3). 370–380. 12 indexed citations

Udagawa, Hibiki, Hiroaki Akamatsu, Kentaro Tanaka, et al.. (2019). Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. Lung Cancer. 135. 145–150. 23 indexed citations

Akamatsu, Hiroaki, Hibiki Udagawa, Kentaro Tanaka, et al.. (2019). Phase I study on preliminary safety and efficacy of rovalpituzumab tesirine in Japanese patients (pts) with advanced, recurrent small cell lung cancer (SCLC).. Journal of Clinical Oncology. 37(15_suppl). 8557–8557. 2 indexed citations

Okamoto, Isamu, Hibiki Udagawa, Shintaro Kanda, et al.. (2017). An open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer. Annals of Oncology. 28. v542–v542. 1 indexed citations

10.

Okubo, Sumiko, et al.. (2012). Two cases of spindle cell carcinoma of the breast – Usefulness of immunohistochemical analysis. 38(1). 33–38. 1 indexed citations

11.

Okubo, Sumiko, et al.. (2012). Safety and Effectiveness of Gemcitabine in 260 Patients with Biliary Tract Cancer in a Japanese Clinical Practice Based on Post-marketing Surveillance in Japan. Japanese Journal of Clinical Oncology. 42(11). 1043–1053. 1 indexed citations

12.

Kurebayashi, Junichi, Sumiko Okubo, Yutaka Yamamoto, et al.. (2006). Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells. Cancer Chemotherapy and Pharmacology. 58(4). 460–470. 47 indexed citations

13.

Kurebayashi, Junichi, Tsunehisa Nomura, Sumiko Okubo, et al.. (2006). Combined Measurement of Serum Sialyl Lewis X with Serum CA15-3 in Breast Cancer Patients. Japanese Journal of Clinical Oncology. 36(3). 150–153. 23 indexed citations

14.

Kurebayashi, Junichi, Yutaka Yamamoto, Masafumi Kurosumi, et al.. (2006). Loss of BRCA1 expression may predict shorter time-to-progression in metastatic breast cancer patients treated with taxanes.. PubMed. 26(1B). 695–701. 30 indexed citations

15.

Sato, Yasushi, et al.. (2005). [A case of granulocyte-colony stimulating factor producing small cell carcinoma of esophagus].. PubMed. 102(7). 888–93. 4 indexed citations

16.

Okubo, Sumiko, Junichi Kurebayashi, Takemi Otsuki, et al.. (2004). Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. British Journal of Cancer. 90(1). 236–244. 54 indexed citations

17.

Ikeda, Masahiko, Junichi Kurebayashi, Hiroshi Sonoo, et al.. (2004). A CASE OF APOCRINE DUCTAL CARCINOMA IN SITU OF THE BREAST WITH AN EXTENSIVE INTRADUCTAL SPREAD FORESEEN BY DYNAMIC MRI OF THE BREAST. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 65(12). 3148–3151. 4 indexed citations

18.

Kurebayashi, Junichi, Sumiko Okubo, Yutaka Yamamoto, & Hiroshi Sonoo. (2004). Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer. 11(1). 38–41. 26 indexed citations

19.

Okubo, Sumiko, Katsuhiro Tanaka, Yutaka Yamamoto, et al.. (2002). A Study on 14 Cases of Thyroid Cancer in Children and Younger Patients.. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 63(10). 2358–2361. 1 indexed citations

20.

Takenaka, Hiroaki, Sachiko Yamazaki, Hiroyuki Yamada, et al.. (1993). [A case report of acute mid-graft occlusion of the left internal mammary artery to the left anterior descending artery after PTCA].. PubMed. 41(12). 1209–12. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact